166 related articles for article (PubMed ID: 37264757)
1. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials.
Jing C; Zhao A; Wang J; Niu T
Cancer Med; 2023 Jul; 12(14):15107-15116. PubMed ID: 37264757
[TBL] [Abstract][Full Text] [Related]
2. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Sheng Z; Wang L
Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.
Wang Y; Zhou S; Qi X; Yang F; Maurer MJ; Habermann TM; Witzig TE; Wang ML; Nowakowski GS
Blood Cancer J; 2022 Jan; 12(1):1. PubMed ID: 34987165
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
[TBL] [Abstract][Full Text] [Related]
6. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
7. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Villa D; Hoster E; Hermine O; Klapper W; Szymczyk M; Bosly A; Unterhalt M; Rimsza LM; Ramsower CA; Freeman CL; Scott DW; Gerrie AS; Savage KJ; Sehn LH; Dreyling M
Blood Adv; 2022 Sep; 6(18):5285-5294. PubMed ID: 35439293
[TBL] [Abstract][Full Text] [Related]
10. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
Robak T; Smolewski P; Robak P; Dreyling M
Leuk Lymphoma; 2019 Nov; 60(11):2622-2634. PubMed ID: 31018735
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Edina BC; Rinaldi I
Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
14. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
Schulz H; Bohlius J; Skoetz N; Trelle S; Kober T; Reiser M; Dreyling M; Herold M; Schwarzer G; Hallek M; Engert A
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003805. PubMed ID: 17943799
[TBL] [Abstract][Full Text] [Related]
16. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
Patel DA; Wan F; Trinkaus K; Guy DG; Edwin N; Watkins M; Bartlett NL; Cashen A; Fehniger TA; Ghobadi A; Shah NM; Kahl BS
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):552-560. PubMed ID: 37183115
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
